Attention Deficit Hyperactivity Disorder Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Attention Deficit Hyperactivity Disorder stocks.

Attention Deficit Hyperactivity Disorder Stocks Recent News

Date Stock Title
Jun 17 LLY Two Is Better Than One in the Alzheimer’s Market
Jun 17 LLY Lilly’s Phase II results in Alzheimer’s disease have most experts saying donanemab is done
Jun 16 LLY Ozempic drives more demand for smaller clothes, WSJ reports
Jun 16 LLY Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
Jun 15 LLY Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?
Jun 15 LLY U.S. drug shortages worsen to reach a decade high: report
Jun 15 LLY Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster
Jun 15 LLY 3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Jun 14 LLY Employee benefits survey finds marked increase in GLP-1 coverage
Jun 14 LLY Top Stock Reports for Berkshire Hathaway, Eli Lilly & PepsiCo
Jun 14 LLY Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
Jun 14 LLY Eli Lilly unveils new manufacturing plant for GLP-1 pens
Jun 14 LLY June consumer sentiment disappoints, Tesla short-selling: Catalysts
Jun 14 LLY Pre-diabetes rates increase amidst a renaissance for type 2 diabetes research
Jun 14 LLY Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 market
Jun 14 LLY Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
Jun 14 LLY The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
Jun 14 LLY Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Jun 14 LLY Employer coverage for GLP-1s rising amid FDA label expansions: survey
Jun 14 LLY Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
Attention Deficit Hyperactivity Disorder

Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It is characterized by difficulty paying attention, excessive activity, or difficulty controlling behavior which is not appropriate for a person's age. The symptoms appear before a person is twelve years old, are present for more than six months, and may cause problems in at least two settings (such as school, home, or recreational activities). In children, problems paying attention may result in poor school performance. Additionally there is an association with other mental disorders and substance misuse. Although it causes impairment, particularly in modern society, many people with ADHD can have sustained attention span for tasks they find interesting or rewarding (known as hyperfocus).Despite being the most commonly studied and diagnosed mental disorder in children and adolescents, the exact cause is unknown in the majority of cases. It affects about 5–7% of children when diagnosed via the DSM-IV criteria and 1–2% when diagnosed via the ICD-10 criteria. As of 2015 it is estimated to affect about 51.1 million people globally. Rates are similar between countries and depend mostly on how it is diagnosed. ADHD is diagnosed approximately two times more often in boys than in girls, although the disorder is often overlooked in girls because their symptoms differ from those of boys. About 30–50% of people diagnosed in childhood continue to have symptoms into adulthood and between 2–5% of adults have the condition. In adults inner restlessness rather than hyperactivity may occur. The condition can be difficult to tell apart from other conditions, as well as to distinguish from high levels of activity that are still within the range of normative behaviors.ADHD management recommendations vary by country and usually involve some combination of counseling, lifestyle changes, and medications. The British guideline only recommends medications as a first-line treatment in children who have severe symptoms and for medication to be considered in those with moderate symptoms who either refuse or fail to improve with counseling, though for adults medications are a first-line treatment. Canadian and American guidelines recommend that medications and behavioral therapy be used together as a first-line therapy, except in preschool-aged children. Stimulant medication therapy is not recommended as a first-line therapy in preschool-aged children in either guideline. Treatment with stimulants is effective for at least 14 months; however, their long term effectiveness is unclear. Adults often develop coping skills which make up for some or all of their impairments.The medical literature has described symptoms similar to those of ADHD since the 18th century. ADHD, its diagnosis, and its treatment have been considered controversial since the 1970s. The controversies have involved clinicians, teachers, policymakers, parents, and the media. Topics include ADHD's causes and the use of stimulant medications in its treatment. Most healthcare providers accept ADHD as a genuine disorder in children and adults, and the debate in the scientific community mainly centers on how it is diagnosed and treated. The condition was officially known as attention-deficit disorder (ADD) from 1980 to 1987, while before this it was known as hyperkinetic reaction of childhood.

Browse All Tags